Impact of axitinib therapy management on adverse event (AE) resolution/improvement (Res/Imp) among advanced renal cell carcinoma (aRCC) patients (Pts) receiving first-line (1L) axitinib plus checkpoint inhibitor (CPI) therapy

被引：0
|
作者：
Huynh, L. [1 ]
Du, S. S. [2 ]
Chang, R. [1 ]
Pi, S. [2 ]
Sundaresan, S. [1 ]
Duh, M. S. [1 ]
Thomaidou, D. [3 ]
Zanotti, G. [4 ]
Zakharia, Y. [5 ]
机构：
[1] Anal Grp Inc, Hlth Econ & Outcomes Res, Boston, MA USA
[2] Anal Grp Inc, Hlth Econ & Outcomes Res, New York, NY USA
[3] Pfizer Hellas, Global Med Affairs, Athens, Greece
[4] Pfizer Inc, Oncol HEOR, New York, NY USA
[5] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.093
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
75P
引用
收藏
页码：S1404 / S1405
页数：2
相关论文
共 50 条
  • [41] Persistence and Compliance Among US Patients Receiving Pazopanib or Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: A Retrospective Claims Analysis
    DaCosta, Stacey A.
    McPheeters, Jeffrey T.
    Burton, Tanya M.
    Nagar, Saurabh P.
    Hackshaw, Michelle D.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2015, 21 (06): : 515 - 522
  • [42] Adverse event (AE) burden of nivolumab-based immunooncology (IO) therapy with/without chemotherapy (chemo) for first-line (1L) advanced non-small cell lung cancer (aNSCLC)
    Schwartzberg, L.
    Wu, A.
    Hartman, J.
    Wang, T.
    Yin, X.
    Chen, J.
    Betts, K. A.
    Lubinga, S. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1069 - S1070
  • [43] Effect of best response to first-line (1L) treatment (tx) on outcomes with second-line (2L) nintedanib (NIN) plus docetaxel (DOC) for patients (pts) with lung adenocarcinoma after 1L immune checkpoint inhibitor (ICI) combination therapy
    Grohe, C.
    Wehler, T. C.
    Henschke, S.
    Dittrich, I.
    Hammerschmidt, S.
    Aulmann, C.
    Dechow, T. N.
    Schiefer, C.
    von der Heyde, E.
    Schuette, W.
    Atz, J.
    Kaiser, R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1072 - S1073
  • [44] Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma
    Ishihara, Hiroki
    Nemoto, Yuki
    Nakamura, Kazutaka
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Kobayashi, Hirohito
    Iizuka, Junpei
    Shimmura, Hiroaki
    Hashimoto, Yasunobu
    Kondo, Tsunenori
    Takagi, Toshio
    TARGETED ONCOLOGY, 2023, 18 (01) : 159 - 168
  • [45] Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma
    Hiroki Ishihara
    Yuki Nemoto
    Kazutaka Nakamura
    Hidekazu Tachibana
    Hironori Fukuda
    Kazuhiko Yoshida
    Hirohito Kobayashi
    Junpei Iizuka
    Hiroaki Shimmura
    Yasunobu Hashimoto
    Tsunenori Kondo
    Toshio Takagi
    Targeted Oncology, 2023, 18 : 159 - 168
  • [46] yyEfficacy of immune-checkpoint inhibitor (ICI) combination as a first-line (1L) therapy in metastatic renal cell carcinoma (mRCC) with sarcomatoid histology: A systematic review and meta-analysis.
    Siddiqi, Rabbia
    Kumar, Gaurav
    Ijaz, Hafsah
    Naqvi, Syed Arsalan Ahmed
    Ayaz, Ahsan
    Bin Riaz, Zaryab
    Bryce, Alan Haruo
    Ho, Thai Huu
    Bin Riaz, Irbaz
    Singh, Parminder
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [47] Outcomes of real-world (RW) patients (pts) with advanced NSCLC (aNSCLC) and high programmed cell death-ligand 1 (PD-L1) expression receiving first line (1L) immune checkpoint inhibitor (ICI) therapy
    Hsu, M. L.
    Ge, W.
    Wu, N.
    Quek, R.
    Liu, J.
    Jalbert, J. J.
    Rietschel, P.
    Feliciano, J.
    Harnett, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1056 - S1056
  • [48] Treatment duration and response of advanced renal cell carcinoma (aRCC) patients (pts) who have completed first-line (1L) treatment (tx): Results from a cross-sectional real-world study
    Zanotti, Giovanni
    Kim, Ruth
    Krulewicz, Stan
    Hall, Jennifer P.
    Leith, Andrea
    Bailey, Abigail
    Liu, Frank Xiaoqing
    Kearney, Mairead
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [49] Re: Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients with Advanced Clear-cell Renal-cell Carcinoma (JAVELIN Renal 100): An Openlabel, Dose-finding and Dose-expansion, Phase 1b Trial
    Gruenwald, Viktor
    Hadaschik, Boris
    EUROPEAN UROLOGY, 2019, 75 (04) : 697 - 698
  • [50] EXPLORING HIDDEN SURVIVAL HETEROGENEITY AMONG FIRST-LINE (1L) INTERMEDIATE/POOR (I/P)-RISK ADVANCED RENAL CELL CARCINOMA (ARCC) PATIENTS TREATED WITH NIVOLUMAB PLUS IPILIMUMAB (NIVO plus IPI) VIA PARAMETRIC MIXTURE MODELS (PMM)
    Hunger, M.
    George, S.
    Dyer, M.
    Ejzykowicz, F.
    May, J. R.
    Kurt, M.
    VALUE IN HEALTH, 2023, 26 (06) : S287 - S287
12345